1α,25-Dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in Human Monocytes

Cytokine

Volumn 45, Issue 3, 2009, Pages 190-197

  Almerighi, Cristiana ^a   Sinistro, Anna ^a   Cavazza, Antonella ^b   Ciaprini, Chiara ^a   Rocchi, Giovanni ^a   Bergamini, Alberto ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

1 ,25 Dihydroxyvitamin D3; CD40L; Cytokine; Monocyte; T cell

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; DIHYDROXYCOLECALCIFEROL; GAMMA INTERFERON; INTERLEUKIN 1BETA; STEROID HORMONE; TUMOR NECROSIS FACTOR ALPHA; CALCITRIOL; IMMUNOLOGIC FACTOR;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CELL TYPE; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; SERUM; DRUG EFFECT; IMMUNOLOGY;

CALCITRIOL; CD40 LIGAND; HUMANS; IMMUNOLOGIC FACTORS; MONOCYTES;

EID: 60649109332     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.12.009     Document Type: Article

References (61)

1. Lemire J.M. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 53 (1995) 599-602
2. Casteels K., Bouillon R., Waer M., and Mathieu C. Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Curr Opin Nephrol Hypertens 4 (1995) 313-318
3. Provvedini D.M., Tsoukas C.D., Deftos L.J., and Manolagas S.C. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221 (1983) 1181-1183
4. Tsoukas C.D., Watry D., Escobar S.S., Provvedini D.M., Dinarello C.A., Hustmyer F.G., et al. Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 69 (1989) 127-133
5. Lemire J.M., Adams J.S., Sakai R., and Jordan S.C. 1, 25-Dihydroxivitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 4 (1984) 657-661
6. Rigby W.F., Denome S., and Fanger M.W. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. J Clin Invest 9 (1987) 1659-1664
7. Müller K., Haahr P.M., Diamant M., Rieneck K., Kharazmi A., and Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 4 (1992) 506-512
8. Rigby W.F., Waugh M., and Graziano R.F. Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3. Blood 76 (1990) 189-197
9. Xu H., Soruri A., Gieseler R.K.H., and Peters J.H. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC-class II antigen expression, accessory activity and phagocytosis of human monocytes. Scand J Immunol 38 (1993) 535-540
10. Clavreul A., D'hellencourt C.L., Montero-Menei C., Potron G., and Couez D. Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes. Immunology 95 2 (1998) 272-277
11. Rigby W.F., and Waugh M.G. Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. Arthritis Rheumatol 35 (1992) 110-119
12. Hollenbaugh D., Ochs H.D., Noelle R.J., Ledbetter J.A., and Aruffo A. The role of CD40 and its ligand in the regulation of the immune response. Immunol Rev 138 (1994) 23-37
13. Grewal I.S., and Flavell R.A. The CD40 ligand: at the centre of the immune universe?. Immunol Res 16 (1997) 59-70
14. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., and Noelle R.J. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 14 (1996) 591-617
15. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell mediated immunity. Annu Rev Immunol 16 (1998) 111-135
16. Graf D., Korthauer U., Mages H.W., Senger G., and Kroczek R.A. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 22 (1992) 3191-3194
17. Alderson M.R., Armitage R.J., Tough T.W., Strockbine L., Fanslow W.C., and Spriggs M.K. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178 (1993) 669-674
18. Brossart P., Grunebach F., Stuhler G., Reichardt V.L., Mohle R., Kanz L., et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 11 (1998) 4238-4247
19. Kiener P.A., Moran-Davis P., Rankin B.M., Wahl A.F., Aruffo A., and Hollenbaugh D. Stimulation of CD40 with purified soluble gp 39 induces proinflammatory responses in human monocytes. J Immunol 155 (1995) 4917-4925
20. Chaussabel D., Jacobs F., de Jonge J., de Veerman M., Carlier Y., and Thielemans K. CD40 ligation prevents trypanosoma cruzi infection through interleukin-12 upregulation. Infect Immun 67 (1999) 1929-1934
21. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., and Routsias J.G.E. Levated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 26 (2006) 165-171
22. Koshy M., Berger D., and Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98 (1996) 826-837
23. Liu M.F., Chao S.C., Wang C.R., and Lei H.Y. Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 34 (2001) 107-113
24. Wang C.R., and Liu M.F. Regulation of CCR5 expression and MIP-1alpha production in CD4+ T cells from patients with rheumatoid arthritis. Clin Exp Immunol 132 (2003) 371-378
25. Harigai M., Hara M., Kawamoto M., Kawaguchi Y., Sugiura T., and Tanaka M. Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kappaB using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis. Arthritis Rheumatol 50 (2004) 2167-2177
26. Jensen J., Krakauer M., and Sellebjerg F. Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis. Eur J Neurol 8 (2001) 321-328
27. Filion L.G., Matusevicius D., Graziani-Bowering G.M., Kumar A., and Freedman M.S. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin Immunol 106 (2003) 127-138
28. Ludwiczek O., Kaser A., and Tilg H. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases. Int J Colorectal Dis 18 (2003) 142-151
29. Kuroiwa T., Lee E.G., Danning G.L., Illei G.G., McInnes I.B., and Boumpas D.T. CD40 ligand-activated human monocytes amplify glomerular inflammatory responses through soluble ans cell-to-cell contact-dependent mechanisms. J Immunol 163 (1999) 2168-2175
30. Kiener P.A., Stout R.D., Blazar B.R., Taylor P.A., Noelle R.J., and Vallera D.A. CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L: CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 102 (1998) 473-482
31. Lederer S.R., Friedrich N., Gruber R., Landgraf R., Toepfer M., and Sitter T. Reduced CD40L expression on ex vivo activated CD4+ T lymphocytes from patients with excellent renal allograft function measured with a rapid whole blood flow cytometry procedure. Int Arch Allergy Immunol 133 (2004) 276-284
32. Grammer A.C., Slota R., Fischer R., Gur H., Girschick H., Yarboro C., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 112 (2003) 1506-1520
33. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., and Balow J.E. BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheumatol 48 (2003) 719-727
34. Liossis S.N., and Sfikakis P.P. Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 18 (2004) 95-102
35. Durie F.H., Aruffo A., Ledbetter J., Crassi K.M., Green W.R., and Fast L.D. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-versus-host disease. J Clin Invest 94 (1994) 1333-1338
36. Guillonneau C., Aubry V., Renaudin K., Séveno C., Usal C., and Tezuka K. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation 80 (2005) 546-554
37. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Buhlman J., Xu J., and Flavell R.A. Blockade of CD40 ligand-CD40 interaction impairs T cell mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 158 (1997) 29-39
38. Canning M.O., Grotenhuis K., de Wit H., Ruwhof C., and Drexhage H.A. 1-alpha, 25-Dihydroxyvitamin D3 (1, 25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 145 (2001) 351-357
39. Placido R., Mancino G., Amendola A., Mariani F., Vendetti S., Piacentini M., et al. Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. J Pathol 181 (1997) 31-38
40. Fried J., Perez A.G., and Clarkson B.D. Rapid hypotonic method for flow cytofluorometry of monolayer cell cultures. Some pitfalls in staining and data analysis. J Hystochem Cytochem 26 (1978) 921-933
41. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring tymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139 (1991) 271-279
42. Bolacchi F., Carbone M., Capozzi M., Ventura L., Cepparulo M., and Rocchi G. Effect of different activation stimuli on the cytokine response of human macrophages to CD40L. Cytokine 16 (2001) 121-125
43. Burger D., Molnarfi N., Gruaz L., and Dayer J.-.M. Differential induction of IL-1β and TNF by CD40 ligand or cellular contact with stimulated T cells depends on the maturation stage of human monocytes. J Immunol 173 (2004) 1292-1297
44. Kato K., Santana-Sahagun E., Rassenti L.Z., Weisman M.H., Tamura N., Kobayashi S., et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 104 (1999) 947-995
45. Tamura N., Kobayashi S., Kato K., Bando H., Haruta K., Oyanagi M., et al. Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 228 (2001) 2583-2590
46. Munger K.L., Zhang S.M., O'Reilly E., Hernán M.A., Olek M.J., Willett W.C., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62 (2004) 60-65
47. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., and Saag K.G. Iowa Women's Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheumatol 50 (2004) 72-77
48. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T Helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 195 (2002) 603-613
49. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogenic immature human dendritic cells. J Exp Med 192 (2000) 1213-1222
50. Penna G., Amuchastegui S., Giarratana N., Daniel K.C., Vulcano M., Sozzani S., et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178 (2007) 145-153
51. Gajewski T.F., Pinnas M., Wong T., and Fitch F.W. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol 146 (1991) 1750-1758
52. Chang T.L., Shea C.M., Urioste S., Thompson R.C., Boom W.H., and Abbas A.K. Heterogeneity of helper/inducer T lymphocytes III. Responses of IL-2- and IL-4-producing (Th1 and Th2) clones to antigens presented by different accessory cells. J Immunol 145 (1990) 2803-2808
53. Damle N.K., Klussman K., Linsley P.S., and Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 148 (1992) 1985-1992
54. Walunas T.L., Bakker C.Y., and Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183 (1996) 2541-2550
55. Bharat A., Fields R.C., Trulock E.P., Patterson G.A., and Mohanakumar T. Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol 177 (2006) 5631-5638
56. Mountz J.D., Wu J., Cheng J., and Zhou L. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheumatol 37 (1994) 1415-1420
57. Manga D.F., Welch G., and Walml S. Lipopolysaccharide, tumor necrosis factor-α, and IL-1 prevent programmed cell death (apoptosis) in human peripheral blood monocytes. J Immunol 146 (1991) 1541-1546
58. Mangan D.F., and Wahl S. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol 147 (1991) 3408-3412
59. Lang R., Patel D., Morris J.J., Rutschman R.L., and Murray P.J. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 169 (2002) 2253-2263
60. Nathan C., and Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 97 (2000) 8841-8848
61. Stein M., Keshav A., Harris N., and Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176 (1992) 287-292